FibroGen to Present at Upcoming Investor Conferences

Rhea-AI Summary

FibroGen, Inc. (NASDAQ: FGEN) announced that CEO Enrique Conterno will participate in two upcoming virtual healthcare conferences: the Jefferies Virtual Healthcare Conference on June 4, 2021, at 10:30 AM ET and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 3:00 PM ET. A live audio webcast will be accessible on the FibroGen Investor webpage, with a replay available for about 30 days. FibroGen focuses on developing innovative therapeutics, including roxadustat for anemia related to chronic kidney disease and pamrevlumab for various conditions.

SAN FRANCISCO, May 27, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following virtual healthcare conferences:

• Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 10:30 AM Eastern Time
  
• Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 3:00 PM Eastern Time
  

A live audio webcast will be available on the “Events & Presentations” section of the FibroGen Investor webpage at www.fibrogen.com. A replay will be available for approximately 30 days.

About FibroGen

FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and idiopathic pulmonary fibrosis (IPF). For more information, please visit www.fibrogen.com.

Contact:
FibroGen, Inc.

Investors:
Michael Tung, M.D.
Corporate Strategy / Investor Relations
mtung@fibrogen.com

Media:
GCI Health
FibroGenMedia@gcihealth.com

FAQ

When will Enrique Conterno participate in the Jefferies Virtual Healthcare Conference?

Enrique Conterno will participate in the Jefferies Virtual Healthcare Conference on June 4, 2021, at 10:30 AM Eastern Time.

What is the date of the Goldman Sachs 42nd Annual Global Healthcare Conference?

The Goldman Sachs 42nd Annual Global Healthcare Conference is scheduled for June 10, 2021, at 3:00 PM Eastern Time.

Where can I find the live audio webcast of FibroGen's conference participation?

The live audio webcast will be available on the 'Events & Presentations' section of the FibroGen Investor webpage at www.fibrogen.com.

What is the main focus of FibroGen's biopharmaceutical development?

FibroGen is focused on discovering and developing therapeutics, particularly roxadustat for anemia associated with chronic kidney disease and pamrevlumab for multiple conditions.